Cargando…
RAGE Signaling in Melanoma Tumors
Despite recent progresses in its treatment, malignant cutaneous melanoma remains a cancer with very poor prognosis. Emerging evidences suggest that the receptor for advance glycation end products (RAGE) plays a key role in melanoma progression through its activation in both cancer and stromal cells....
Autores principales: | Olaoba, Olamide T., Kadasah, Sultan, Vetter, Stefan W., Leclerc, Estelle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730603/ https://www.ncbi.nlm.nih.gov/pubmed/33256110 http://dx.doi.org/10.3390/ijms21238989 |
Ejemplares similares
-
Hypoxia and the Receptor for Advanced Glycation End Products (RAGE) Signaling in Cancer
por: Taneja, Sakshi, et al.
Publicado: (2021) -
The S100B/RAGE Axis in Alzheimer's Disease
por: Leclerc, Estelle, et al.
Publicado: (2010) -
RAGE Up-Regulation Differently Affects Cell Proliferation and Migration in Pancreatic Cancer Cells
por: Swami, Priyanka, et al.
Publicado: (2020) -
Making Sense of “Nonsense” and More: Challenges and Opportunities in the Genetic Code Expansion, in the World of tRNA Modifications
por: Lateef, Olubodun Michael, et al.
Publicado: (2022) -
Cancer Immunotherapy and Delivery System: An Update
por: Yang, Ming, et al.
Publicado: (2022)